Murine Anti-mCD4 mAb

Anti-mCD4-mIgG2a InvivoFit™ Unit size Cat. code Docs Qty Price
GK1.5-derived mouse monoclonal antibody against murine CD4
1 mg
10 mg

You may also need : Murine IgG2a Isotype Control | View more associated products

Recombinant mouse mAb against murine CD4 for in vivo use

InvivoGen’s engineered Anti-mCD4-mIgG2a InvivoFit™ antibody
InvivoGen’s engineered Anti-mCD4-mIgG2a InvivoFit™ antibody

Anti-mCD4-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCD4 GK1.5 clone [1]. Using recombinant technology, the original GK1.5 rat IgG2b constant region has been replaced with a murine IgG2a format which mediates potent cytotoxic functions [2].

The anti-mCD4 GK1.5 mAb is commonly used for in vivo depletion of the CD4+ T cell population to study the role of this T cell subset in various immune responses, including anti-pathogenic responses, auto-immunity, cancer, or transplantation [3]. Depending on the nature of the experiment, extended treatment schedules (up to several months) may be required. Upon repeated injection of a xenogeneic mAb, mice produce anti–species antibodies, causing the removal of the administered mAb from circulation, thereby considerably reducing treatment efficacy. Moreover, this immunogenicity can lead to fatal hypersensitivity reactions [3-5] which can be reduced by mAb murinization [6].

CD4 background:

The cluster of differentiation 4 (CD4) receptor (formerly named L3T4, or T4) is a 55 kDa transmembrane protein primarily expressed on most thymocytes, and highly expressed by the peripheral mature CD4+ T cell population, including T helper (Th) and regulatory T (Treg) cells [7]. Other immune cells, such as monocytes and macrophages also express CD4, albeit to 10- to 20-fold fewer levels compared to T cells [8]. Besides its role in the positive selection and development of CD4+ T cells, the CD4 receptor plays a critical role during their activation. It fulfills an intercellular adhesion function by interacting with the α2 or β2 domain of MHC class II molecules, thereby stabilizing the interaction between the TCR on the T cell and the MHC-peptide complex on the antigen-presenting cell [9]. Upon antigen recognition, the proximity association of CD4 and the TCR/CD3 complex on T cells triggers downstream intracellular signaling and participates in the T helper differentiation [7].

Key features of Anti-mCD4-mIgG2a InvivoFit™:

  • Derives from the GK1.5 clone, rat IgG2b, κ
  • Features the mIgG2a isotype (constant region)
  • Guaranteed sterile, endotoxin level < 1 EU/mg
  • Suitable for parental delivery in mice (azide-free)
  • Low aggregation < 5%
  • Produced in animal-free facilities and defined media

Anti-mCD4-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and provided in an InvivoFit grade, a high-quality standard specifically adapted to in vivo studies. The specific binding of this mAb to cell surface mCD4 and its in vivo depleting function have been confirmed (see Figures).



1. Dialynas D.P. et al., 1983. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev. 74:29-56
2. Nimmerjahn F. & Ravetch J.V., 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310(5753):1510-2.
3. Laky K. & Kruisbeek A.M., 2016. In vivo depletion of T lymphocytes. Current Protocols Immunology. 4.1.1-4.1.9. doi: 10.1002/0471142735.im0401s113.
4. Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogenic hypersensitivity reactions in a murine model of breast cancer. Onco Immunol. 5(2):e1075114.
5. Murphy, J.T. et al., 2014. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 123(14):2172-2180.
6. Belmar N.A. et al., 2017. Murinization and H chain isotype matching of Anti-GITR antibody DTA-1 reduces immunogenicity-mediated anaphylaxis in C57BL/6 mice. J Immunol. 198:4502-4512.
7. Zhu J. et al., 2010. Differentiation of effector CD4 T cell populations. Annual Rev Immunol. 28:445-489.
8. Collman R. et al., 1990. Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol. 64(9):4468-76.
9. Doyle C. & Strominger J.L., 1987. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256-259.


Validation of Anti-mCD4-mIgG2a binding by FACS
Validation of Anti-mCD4-mIgG2a binding by FACS

Cell surface staining of murine CD4 using Anti-mCD4-mIgG2a InvivoFit™ mAb.
~5x105 Jurkat (parental) or Jurkat-mCD4 cells were incubated with 2 μg of Anti‑mCD4‑mIgG2a InvivoFit™ mAb or an isotype control for 1h at 4°C. Cells were then washed and incubated with 0.25 μg of goat anti-mouse κ-light chain coupled to PE for 1h at 4°C. Cell surface staining was analyzed by flow cytometry.

Validation of in vivo CD4 + T cell depletion using Anti-mCD4-mIgG2a InvivoFit™
Validation of in vivo CD4 + T cell depletion using Anti-mCD4-mIgG2a InvivoFit™

Analysis of CD4+ T cell population in mice peripheral blood upon injection of Anti-mCD4-mIgG2a InvivoFit™ mAb.
Blood samples (20 μl) from SWR/J mice aged 10 weeks were harvested 1 week prior to a series of intraperitoneal (IP) injections with the depleting Anti‑mCD4‑mIgG2a InvivoFit™ mAb (200 μg) or NaCl (control), and 24h after each IP injection. IP injections were performed at day 0, +3, and +7 (arrows). Thereafter, blood samples were harvested once a week. To assess the kinetics of the in vivo depletion of CD4+ T cells, peripheral blood was stained with the following conjugated antibodies: Anti-CD45-Pe-Cy7 (clone 30-F11), Anti-CD3e-PE (clone 145-2C11), Anti-CD4-FITC (clone RMA-4), and Anti-CD8-APC (clone H35-17.2) according to standard procedures. Cell surface staining was analyzed by flow cytometry. Data are represented as the frequency of CD4+ T cells among the total CD3+ T cell population.

Back to the top


Specificity: Targets cells expressing murine CD4

Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose

Clonality: Monoclonal antibody

Isotype: Murine IgG2a, kappa

Source: CHO cells

Purity: Purified by affinity chromatography with protein A

Tested application: Flow cytometry; in vivo depletion

Quality control:

  • Binding of Anti-mCD4-mIgG2a InvivoFit™ to mCD4 has been confirmed using Flow cytometry
  • Mouse CD4+ T cell in vivo depletion using Anti-mCD4-mIgG2a InvivoFit™ has been confirmed
  • The complete sequence of the antibody  construct has been verified
  • < 5% aggregates (confirmed by size exclusion chromatography)
  • Guaranteed sterile and <1 EU/mg (determined by the LAL assay)
Back to the top


Anti-mCD4-mIgG2a InvivoFit™ is provided sterile, endotoxin-free, azide-free, and lyophilized.  

This product is available in two pack sizes:

  • mcd4-mab10-1​: 1 mg
  • mcd4-mab10-10​: 10 mg


room temperature The product is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

stability Lyophilized product is stable for at least 1 year

Alert Avoid repeated freeze-thaw cycles.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty